Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Print publication year: 2010
  • Online publication date: May 2010

Chapter 17 - Conclusion and implications for practice and policy

Export citation
Summary
Multiple factors contribute to high levels of cardiovascular (CV) risk in schizophrenia patients including lifestyle habits. The additive CV effects of cigarette smoking, hypertension, total cholesterol, and high density lipoprotein (HDL) cholesterol have been found to predict the risk of major cardiac events over a 10 year period. These effects can be calculated with empirically derived CV risk algorithms. By the time the initial Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) analysis of metabolic syndrome prevalence was performed in 2005, there was already a signal that schizophrenia patients had 2-4 times higher prevalence than that expected from general population estimates. The CATIE schizophrenia trial data illustrate the possibility for improving metabolic health by switching patients from more offending medications, and for avoiding long-term CV consequences by preferential use of agents with metabolically benign profiles. Management of schizophrenia requires acknowledgment that CV disease remains a primary cause of excess mortality.

Keywords:

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Antipsychotic Trials in Schizophrenia
  • Online ISBN: 9780511712265
  • Book DOI: https://doi.org/10.1017/CBO9780511712265
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×

References

1. SimonGE, PsatyBM, HrachovecJB, et al. Principles for evidence-based drug formulary policy. Journal of General Internal Medicine 2005;20:964–8.
2. EssockSM, CovellNH, DavisSM, et al. Effectiveness of switching antipsychotic medications. American Journal of Psychiatry 2006;163:2090–5.
3. DavisJM, ChenN and GlickID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003;60:553–64.
4. LeuchtS, CorvesC, ArbterD, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009;737:31–41.
5. CorrellCU, LeuchtS and KaneJM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 2004;161:414–25.
6. HamiltonSH, RevickiDA, EdgellET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia – results from a randomized clinical trial. Pharmacoeconomics 1999;15:469–80.
7. MarderSR and MeibachRC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994;151:825–35.
8. TollefsonGD, BeasleyCM Jr, TranPV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry 1997;154:457–65.
9. CsernanskyJG, MahmoudR and BrennerR. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002;346:16–22.
10. CarpenterWT and ThakerGK. Editorial: Evidence based therapeutics: Introducing the Cochrane Corner. Schizophrenia Bulletin 2007;33:633–4.
11. GeddesJR, FreemantleN, HarrisonP, et al. Atypical antipsychotics in the treatment of schizophrenia – systematic overview and meta-regression analysis. British Medical Journal 2000;321:1371–6.
12. HustonP and MoherD. Redundancy, disaggregation, and the integrity of medical research. Lancet 1996;347:1024–6.
13. RosenheckRA, PerlickD, BinghamS, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 2003;290:2693–702.
14. RosenheckRA. Efficacy vs. effectiveness of second-generation antipsychotics: Haloperidol without prophylactic anticholinergics as a comparitor. Psychiatric Services 2005;56:85–92.
15. HugenholtzGW, HeerdinkER, StolkerJJ, et al. Haloperidol dose when used as active comparitor in randomized controlled trials with atypical antipsychotics in schizophrenia: Comparison with officially recommended doses. Journal of Clinical Psychiatry 2006;67:897–903.
16. DavisJM, ChenN and GlickID. Issues that may determine the outcome of antipsychotic trials: Industry sponsorship and extrapyramidal side effects. Neuropsychopharmacology 2007;33:971–5.
17. LiebermanJA, StroupTS, McEvoyJP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
18. JonesPB, BarnesTRE, DaviesL, et al. Randomized controlled trial of effect on quality of life of second-generation versus first-generation antipsychotic drugs in schizophrenia – CUtLASS1. Archives of General Psychiatry 2006;63:1079–87.
19. DaviesLM, LewisS, JonesPB, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. The British Journal of Psychiatry 2007;191:14–22.
20. PolskyD, DoshiJA, BauerMS, et al. Clinical trial-based cost-effectiveness analyses of antipsychotic use. American Journal of Psychiatry 2006;163:2047–56.
21. DugganM. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. Journal of Health Economics 2005;24:1–31.
22. KaneJM, MeltzerHY, CarsonWH, et al. Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry 2007;68:213–23.
23. RosenheckRA, LeslieDL, BuschS, et al. Rethinking antipsychotic formulary policy. Schizophrenia Bulletin 2008;34:375–80.
24. KahnRS, FleischhackerWW, BoterH, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008;371:1085–97.
25. SikichL, FrazierJA, McClellanJ, et al. Double-blind comparison of first- and second-generation antipsychotics in early onset schizophrenia and schizoaffective disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. American Journal of Psychiatry 2008;165:1420–31.
26. LeuchtS, KomossaK, Rummel-KlugeC, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166:152–63.
27. OwensDC. What CATIE did: Some thoughts on implications deep and wide. Psychiatric Services 2008;59:530–3.
28. RosenheckR, CranerJ, XuW, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on clozapine in refractory schizophrenia. New England Journal of Medicine 1997;337:809–15.
29. BreierA, BergPH, ThakoreJH, et al. Olanzapine versus ziprasidone: Results of a 28-week double blind study in patients with schizophrenia. American Journal of Psychiatry 2005;162:1879–87.
30. FreedmanR, CarpenterWT, DavisJM, et al. The cost of drugs for schizophrenia. American Journal of Psychiatry 2006;163:2029–31.
31. American Diabetes Association (ADA), American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.
32. CorrellCU, LeuchtS and KaneJM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 2004;161:414–25.
33. SwansonJW, SwartzMS, Van DornRA, et al. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry 2006;63:490–9.
34. RosenheckRA, HoffRA, SteinwachsD, et al. Benchmarking treatment of schizophrenia: A comparison of service delivery by the national government and by state and local providers. Journal of Nervous and Mental Disease 2000;188:209–16.
35. KelseyJL, WhittemoreAS, EvansAS, et al. Methods in Observational Epidemiology. 2nd ed. New York: Oxford University Press; 1996. pp 88–9.
36. LastJM, ed. A Dictionary of Epidemiology. 3rd ed. New York: Oxford University Press; 1996.
37. MeltzerHY and BoboWV. Interpreting the efficacy findings in the CATIE study: What clinicians should know. CNS Spectrum 2006;11(Suppl. 7):14–24.
38. KaneJM. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Journal of Clinical Psychiatry 2006;76:831–2.
39. TandonR and ConstatineR. Avoiding EPS is key to realizing “atypical benefits”. Current Psychiatry 2006;5:35–45.
40. RosackJ. Experts say tread slowly when trying to interpret study results. Psychiatric News 2006;41:23.
41. GoodeE. Leading drugs for psychosis come under scrutiny. NY Times May 20, 2003, p. A1.
42. FreedmanR. The choice of antipsychotic drugs for schizophrenia. New England Journal of Medicine 2005;353:1286–8.
43. GanguliR, StrassnigM. Are older antipsychotic drugs obsolete: No. British Medical Journal 2006;332:1345–6.
44. LewisS and LiebermanJA. CATIE and CUtLASS: Can we handle the truth?British Journal of Psychiatry 2008;192:161–3.
45. NasrallahH. The role of efficacy, safety, and tolerability in antipsychotic effectiveness: Practical implications of the CATIE schizophrenia trial. Journal of Clinical Psychiatry 2007;68(Suppl. 1):5–11.
46. SharfsteinS. Antipsychotics, economics and the press. Psychiatric News 2005;40:3.
47. New York Times. Editorial: Comparing schizophrenia drugs. New York Times, 2005 September 21. http://www.nytimes.com/2005/09/21/opinion/21wed3.html?ex=1183953600&en=1cadcb61b264f0c5&ei=5070.
48. VedantamS. New antipsychotic drugs criticized Federal study finds no benefit over older, cheaper drug. Washington Post, September 20, 2005, A0.
49. AbramsonJ. Overdosed America: The Broken Promise of American Medicine. New York, NY: Harper Collins; 2004.
50. AngelM. The Truth About the Drug Companies: How They Deceive Us and What to do About It. New York, NY: Random House; 2004.
51. AvornJ. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York, NY: Knopf; 2004.
52. KassirerJ. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health. New York, NY: Oxford University Press; 2004.
53. MooreTA, BuchananRW, BuckleyPF, et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. Journal of Clinical Psychiatry 2007;68:1751–62.
54. ParksJ, RadkeA, ParkerG, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophrenia Bulletin 2009;35:931–6.
55. CarpenterWT and BuchananRW. Lessons to take home from CATIE. Psychiatric Services 2008;59:523–5.
56. SernyakMJ, LeslieD and RosenheckRA. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatric Services 2008;59:567–9.
57. CascadeE and KalaliA. One of antipsychotics pre-and post dissemination of the CATIE data. Psychiatry 2007;4:21–3.
58. CitromeL, JaffeA, MartelloD, et al. Did CATIE influence antipsychotic use?Psychiatric Services 2008;59:476.
59. UbelPA. Pricing Life: Why Its Time for Health Care Rationing. Cambridge, MA: MIT Press; 2001.
60. DominoME and SwartzMS. Who are the new users of antipsychotic medications?Psychiatric Services 2008;59:507–14.
61. BriesacherBA, LimcangcoMR, Simoni-WastilaL, et al. The quality of antipsychotic drug prescribing in nursing homes. Archives of Internal Medicine 2005;165:1280–5.
62. SchneiderLS, TariotPN, DagermanKS, et al. CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 2006;355:1525–38.
63. HoadleyJ. Cost Containment Strategies for Prescription Drugs: Assessing the Evidence in the Literature. Health Policy Institute. Georgetown University; 2005. http://www.kff.org/rxdrugs/7295.cfm.
64. WeisfeldtML and ZiemanSJ. Advances in the prevention and treatment of cardiovascular disease. Health Affairs (Millwood) 2007;26:25–37 (cf. p. 29).
65. LawMR, Ross-DegnanD and SoumeraiSB. Effect of prior authorization on second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatric Services 2008;59:540–6.
66. SoumeraiSB, ZhangF, Ross-DegnanD, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs (Millwood) 2008;27:w185–w195.
67. DuckworthK and FitzpatrickMJ. NAMI perspective on CATIE: policy and research indications. Psychiatric Services 2008;59:537–40.
68. CovellNH, FinnertyMT and EssockSM. Implications for CATIE for mental health services researchers. Psychiatric Services 2008;59:526–9.
69. FrankRG. Policy toward second-generation antipsychotic drugs: A cautionary note. Psychiatric Services 2008;59:521–2.
70. GoldmanDP, JoyceGF, EscarceJJ, et al. Pharmacy benefits and the use of drugs by the chronically-ill. Journal of the American Medical Association 2004;291:2344–50.
71. HuskampHA, DeverkaPA, EpsteinAM, et al. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Archives of General Psychiatry 2005;62:435–41.
72. SoumeraiSB, McLaughlinTJ, Ross-DegnanD, CasterisCS and BolliniP. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 1994;331:650–5.
73. PolinskiJM, WangPS and FischerMA. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Affairs (Millwood) 2007;26:759–60.
74. DeAngelisCD and FontanarosaPB. Impugning the integrity of medical science: The adverse effects of industry influence. Journal of the American Medical Association 2008;299:1833–5.
75. TurnerEH, MatthewsAM, LinardatosE, TellRA and RosenthalR. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008;358:252–60.
76. RennieD. Fair conduct and fair reporting of clinical trials. Journal of the American Medical Association 1999;282:1766–8.
77. YanJ. Experts disagree on impact of medicine, industry relationship. Psychiatric News 2008;43:1.
78. PetersonM. Our Daily Meds. New York: Sarah Crichton Books-Farrar, Straus and Giroux; 2008.
Cancel
Confirm
×